Komori
Other Disclosures2160GNI Group Ltd.Pharmaceuticals

Questions from institutional investors and answers at the Jefferies Global Healthcare Conference

The company disclosed questions from institutional investors and its responses concerning the CEO's fireside chat and investor meetings at the Jefferies Global Healthcare Conference. It explained the approval and sales outlook for F351, the status of Ayumi Pharmaceutical, its development pipeline and future growth targets.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
470
¥100 million (current group sales revenue level)
Wording
Avoiding a definitive answer
How definitive the wording is.

Announced details

F351AisuruiTargeted protein degradersTRK protein degraderGSPT1 protein degraderCDK2 protein degraderTYK2 protein degraderAesthetic medical products
Applicable field (uses covered by this announcement)
Liver fibrosis associated with hepatitis BCancerImmune and inflammatory diseases, including rheumatic diseasesAesthetic Medicine
Launch dateF351 is expected to launch in the first half of 2027, subject to regulatory approval.
What the company reported numerically
Quantitative Effects

Royalties equivalent to 8–16% of F351's annual sales revenue. The number of F351 patients in China alone is estimated to reach several million at peak.

Usage history

Ayumi Pharmaceutical recorded sales revenue of ¥10.8 billion and operating profit of ¥1.8 billion from July to September 2026. Gyre Pharmaceuticals covers thousands of hospitals.

Relationship between the counterparty and the company
GNI Group Ltd.2160
Relationship with the Company

Gyre Therapeutics and Gyre Pharmaceuticals are affiliated companies of the group. 上海ジェノミックス is a wholly owned subsidiary of the company. The group has an intercompany licensing agreement for F351. Ayumi Pharmaceutical became a group company after being made a subsidiary.

CounterpartyChina's National Medical Products Administration (NMPA)Gyre Therapeutics(NASDAQ: GYRE)Gyre Pharmaceuticalsあゆみ製薬上海ジェノミックスJefferies

NMPA is China's drug regulatory authority. Gyre Therapeutics is listed on the Nasdaq Stock Market in the United States. 上海ジェノミックス is a wholly owned subsidiary of the company. Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people in China, covering thousands of hospitals. Ayumi Pharmaceutical has a domestic sales network and production capabilities in the pain and rheumatology fields.

Location (as indicated in this announcement)

London, UK (conference venue)

Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people, covering thousands of hospitals
Impact on Business Performance

F351 is an important drug candidate expected to drive medium- to long-term growth and contribute to sales and profit growth upon launch. The group aims to grow to several times its current group sales revenue of approximately ¥47 billion.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

The disclosure contains wording suggesting information published by the World Health Organization and other organizations, but does not identify the specific organizations in the main text. It states that market data and other information were cited from publicly available sources deemed reliable.

Announced details
ItemDetails
Names of Products / Services CoveredF351, Aisurui, Targeted protein degraders, TRK protein degrader, GSPT1 protein degrader, CDK2 protein degrader, TYK2 protein degrader, Aesthetic medical products
CounterpartyChina's National Medical Products Administration (NMPA), Gyre Therapeutics(NASDAQ: GYRE), Gyre Pharmaceuticals, あゆみ製薬, 上海ジェノミックス, Jefferies
Counterparty overviewNMPA is China's drug regulatory authority. Gyre Therapeutics is listed on the Nasdaq Stock Market in the United States. 上海ジェノミックス is a wholly owned subsidiary of the company. Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people in China, covering thousands of hospitals. Ayumi Pharmaceutical has a domestic sales network and production capabilities in the pain and rheumatology fields.
Relationship with the CompanyGyre Therapeutics and Gyre Pharmaceuticals are affiliated companies of the group. 上海ジェノミックス is a wholly owned subsidiary of the company. The group has an intercompany licensing agreement for F351. Ayumi Pharmaceutical became a group company after being made a subsidiary.
Launch dateF351 is expected to launch in the first half of 2027, subject to regulatory approval.
Applicable areaLiver fibrosis associated with hepatitis B, Cancer, Immune and inflammatory diseases, including rheumatic diseases, Aesthetic Medicine
LocationLondon, UK (conference venue)
Location scaleGyre Pharmaceuticals has a sales and marketing organization of approximately 400 people, covering thousands of hospitals
Quantitative EffectsRoyalties equivalent to 8–16% of F351's annual sales revenue. The number of F351 patients in China alone is estimated to reach several million at peak.
Usage historyAyumi Pharmaceutical recorded sales revenue of ¥10.8 billion and operating profit of ¥1.8 billion from July to September 2026. Gyre Pharmaceuticals covers thousands of hospitals.
Impact on Business PerformanceF351 is an important drug candidate expected to drive medium- to long-term growth and contribute to sales and profit growth upon launch. The group aims to grow to several times its current group sales revenue of approximately ¥47 billion.
SourceThe disclosure contains wording suggesting information published by the World Health Organization and other organizations, but does not identify the specific organizations in the main text. It states that market data and other information were cited from publicly available sources deemed reliable.
Items this document does not state (6)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry date

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To enhance information dissemination and ensure fair disclosure.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Questions from institutional investors and answers at the Jefferies Global Healthcare Conference | GNI Group Ltd. (2160) timely disclosure | Komori